{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:21Z","timestamp":1792839741461,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The increase in opioid use disorder among young, nonurban people has fueled sharp rises in hepatitis C virus (HCV) infections. Innovative treatment models are needed that circumvent healthcare system barriers for people who use drugs (PWUD), particularly in rural areas. The Oregon HOPE TeleHCV study randomized PWUD living with HCV in rural Oregon to peer-facilitated and streamlined telemedicine HCV treatment (Peer TeleHCV) versus enhanced usual care (EUC) and assessed sustained virologic response at 12\u00a0weeks post treatment (SVR12). Peer Support Specialists (peers) conducted HCV screening in the community, facilitated pretreatment evaluation and linkage to telemedicine HCV treatment clinicians, and supported Peer TeleHCV study participants in HCV medication adherence. A qualitative investigation queried telemedicine clinicians and peers about their experiences with the implementation of the model and key drivers of implementation effectiveness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Two remote audio\/video recorded focus groups were conducted, one with the study\u2019s clinicians and one with the peers. Participants were asked their views of key elements for successful implementation and outcomes of the Peer TeleHCV model. Group interviews lasted one hour. Recordings were professionally transcribed for thematic analysis with a mixed deductive and inductive framework, using Atlas.ti. Patients were surveyed about their interactions and satisfaction with peers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Quantitative data (n\u2009=\u200978) indicated patients had high levels of satisfaction with and support from the peers. Three themes were identified from the qualitative data (n\u2009=\u200912) including. (1) Key peer-level elements such as providing support during potentially difficult lab draws, creating a peer-facilitated \u201cbubble of trust\u201d between patients and clinicians, enabling technology access, conducting outreach to maintain contact and support treatment retention, and facilitating stabilizing wrap-around services (e.g., housing vouchers) (2) Key clinician-level factors such as capacity for unscheduled peer-facilitated appointments, having dedicated time for case consults with peers, and clinicians trained in working with PWUD and skilled in identifying related clinical concerns (3) Key systems-level elements such as standing lab orders, challenges related to specialty pharmacies and Medicaid managed care organizations, and streamlined communication strategies between peers and clinicians.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>All participants reported that the Peer TeleHCV model built trust and eased barriers for PWUD initiating and remaining in HCV treatment. This low-barrier model makes space for PWUD to receive HCV treatment, regardless of drug use. Implementing support from peer specialists, telemedicine technology, and streamlined testing and treatment strategies may connect more rural PWUD living with HCV with the cure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00541-6","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:01:31Z","timestamp":1738998091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Peer-assisted telemedicine hepatitis-C treatment for people who use drugs in rural communities: a mixed methods study"],"prefix":"10.1186","volume":"20","author":[{"given":"Kim","family":"Hoffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Leichtling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonhi","family":"Gailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter C.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"issue":"3","key":"541_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0000000000001098","volume":"73","author":"MM Van Handel","year":"2016","unstructured":"Van Handel MM, Rose CE, Hallisey EJ, et al. County-level vulnerability assessment for rapid dissemination of HIV or hcv infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323\u201331. https:\/\/doi.org\/10.1097\/QAI.0000000000001098.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"541_CR2","unstructured":"Hepatitis C Surveillance in the United States, 2018 | CDC. November 18, 2020. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2018surveillance\/HepC.htm. Accessed 4 June 2021."},{"issue":"2","key":"541_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11904-018-0390-3","volume":"15","author":"DC Perlman","year":"2018","unstructured":"Perlman DC, Jordan AE. The syndemic of opioid misuse, overdose, HCV, and HIV: structural-level causes and interventions. Curr HIV\/AIDS Rep. 2018;15(2):96\u2013112. https:\/\/doi.org\/10.1007\/s11904-018-0390-3.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"541_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11904-018-0393-0","volume":"15","author":"AJ Schranz","year":"2018","unstructured":"Schranz AJ, Barrett J, Hurt CB, Malvestutto C, Miller WC. Challenges facing a rural opioid epidemic: treatment and prevention of HIV and hepatitis C. Curr HIV\/AIDS Rep. 2018;15(3):245\u201354. https:\/\/doi.org\/10.1007\/s11904-018-0393-0.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"541_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103930","volume":"112","author":"SM Walters","year":"2023","unstructured":"Walters SM, Frank D, Felsher M, et al. How the rural risk environment underpins hepatitis C risk: qualitative findings from rural southern Illinois, United States. Int J Drug Policy. 2023;112: 103930. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103930.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"541_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1001\/jamainternmed.2022.0170","volume":"182","author":"B Eckhardt","year":"2022","unstructured":"Eckhardt B, Mateu-Gelabert P, Aponte-Melendez Y, et al. Accessible hepatitis C care for people who inject drugs: a randomized clinical trial. JAMA Intern Med. 2022;182(5):494\u2013502. https:\/\/doi.org\/10.1001\/jamainternmed.2022.0170.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"541_CR7","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","volume":"67","author":"AASLD-IDSA HCV Guidance Panel","year":"2018","unstructured":"AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67(10):1477\u201392. https:\/\/doi.org\/10.1093\/cid\/ciy585.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"541_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.drugpo.2019.03.015","volume":"72","author":"EB Williams","year":"2019","unstructured":"Williams EB, Nelons D, Seaman A, et al. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs. Int J Drug Policy. 2019;72:138\u201345. https:\/\/doi.org\/10.1016\/j.drugpo.2019.03.015.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"541_CR9","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1111\/add.14731","volume":"114","author":"C Barbosa","year":"2019","unstructured":"Barbosa C, Fraser H, Hoerger TJ, et al. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addict Abingdon Engl. 2019;114(12):2267\u201378. https:\/\/doi.org\/10.1111\/add.14731.","journal-title":"Addict Abingdon Engl"},{"issue":"11","key":"541_CR10","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","volume":"3","author":"B Hajarizadeh","year":"2018","unstructured":"Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754\u201367. https:\/\/doi.org\/10.1016\/S2468-1253(18)30304-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"541_CR11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jvh.13119","volume":"26","author":"AH Litwin","year":"2019","unstructured":"Litwin AH, Drolet M, Nwankwo C, et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE Study. J Viral Hepat. 2019;26(9):1094\u2013104. https:\/\/doi.org\/10.1111\/jvh.13119.","journal-title":"J Viral Hepat"},{"issue":"36","key":"541_CR12","doi-asserted-by":"publisher","first-page":"12722","DOI":"10.3748\/wjg.v20.i36.12722","volume":"20","author":"A Arain","year":"2014","unstructured":"Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol. 2014;20(36):12722\u201333. https:\/\/doi.org\/10.3748\/wjg.v20.i36.12722.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"541_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/liv.13949","volume":"39","author":"E Day","year":"2019","unstructured":"Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int Off J Int Assoc Study Liver. 2019;39(1):20\u201330. https:\/\/doi.org\/10.1111\/liv.13949.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"4","key":"541_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11904-018-0402-3","volume":"15","author":"JR Havens","year":"2018","unstructured":"Havens JR, Walsh SL, Korthuis PT, Fiellin DA. Implementing treatment of opioid-use disorder in rural settings: a focus on HIV and hepatitis C prevention and treatment. Curr HIV\/AIDS Rep. 2018;15(4):315\u201323. https:\/\/doi.org\/10.1007\/s11904-018-0402-3.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"541_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109711","volume":"242","author":"C Lin","year":"2022","unstructured":"Lin C, Pham H, Zhu Y, et al. Telemedicine along the cascade of care for substance use disorders during the COVID-19 pandemic in the United States. Drug Alcohol Depend. 2022;242: 109711. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109711.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"541_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/cid\/ciy899","volume":"69","author":"AH Talal","year":"2019","unstructured":"Talal AH, Andrews P, Mcleod A, et al. Integrated, co-located, telemedicine-based treatment approaches for hepatitis C virus management in opioid use disorder patients on methadone. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019;69(2):323\u201331. https:\/\/doi.org\/10.1093\/cid\/ciy899.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"23","key":"541_CR17","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1056\/NEJMoa1009370","volume":"364","author":"S Arora","year":"2011","unstructured":"Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa1009370.","journal-title":"N Engl J Med"},{"issue":"4","key":"541_CR18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.amjmed.2016.11.019","volume":"130","author":"LA Beste","year":"2017","unstructured":"Beste LA, Glorioso TJ, Ho PM, et al. Telemedicine specialty support promotes hepatitis C treatment by primary care providers in the department of veterans affairs. Am J Med. 2017;130(4):432-438.e3. https:\/\/doi.org\/10.1016\/j.amjmed.2016.11.019.","journal-title":"Am J Med"},{"issue":"1","key":"541_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/ADM.0000000000000810","volume":"16","author":"E Stack","year":"2022","unstructured":"Stack E, Hildebran C, Leichtling G, et al. peer recovery support services across the continuum: in community, hospital, corrections, and treatment and recovery agency settings\u2014a narrative review. J Addict Med. 2022;16(1):93\u2013100. https:\/\/doi.org\/10.1097\/ADM.0000000000000810.","journal-title":"J Addict Med"},{"key":"541_CR20","doi-asserted-by":"publisher","unstructured":"Francia L, Berg A, Lam T, Morgan K, Nielsen S. 2022; \u201cThe peer workers, they get it\u201d\u2014how lived experience expertise strengthens therapeutic alliances and alcohol and other drug treatment-seeking in the hospital setting. Addict Res Theory. https:\/\/doi.org\/10.1080\/16066359.2022.2124245","DOI":"10.1080\/16066359.2022.2124245"},{"key":"541_CR21","unstructured":"Substance Abuse and Mental Health Services Administration. Financing Peer Recovery Support: Opportunities to Enhance the Substance Use Disorder Workforce Pub No PEP23-06-07-003. Substance Abuse and Mental Health Services Administration; 2024."},{"issue":"1","key":"541_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1477-7517-10-7","volume":"10","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J. 2013;10(1):7. https:\/\/doi.org\/10.1186\/1477-7517-10-7.","journal-title":"Harm Reduct J"},{"issue":"1","key":"541_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13722-023-00384-z","volume":"18","author":"MC Herink","year":"2023","unstructured":"Herink MC, Seaman A, Leichtling G, et al. A randomized controlled trial for a peer-facilitated telemedicine hepatitis c treatment intervention for people who use drugs in rural communities: study protocol for the \u201cpeer tele-HCV\u201d study. Addict Sci Clin Pract. 2023;18(1):35. https:\/\/doi.org\/10.1186\/s13722-023-00384-z.","journal-title":"Addict Sci Clin Pract"},{"key":"541_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae520","author":"A Seaman","year":"2024","unstructured":"Seaman A, Cook R, Leichtling G, et al. Peer-assisted telemedicine for hepatitis C in people who use drugs: a randomized controlled trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae520.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"541_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/16094069221127068","author":"B Lobe","year":"2022","unstructured":"Lobe B, Morgan D, Hoffman K. A systematic comparison of in-person and video-based online interviewing. Int J Qual Res. 2022. https:\/\/doi.org\/10.1177\/16094069221127068.","journal-title":"Int J Qual Res"},{"issue":"1","key":"541_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13722-021-00277-z","volume":"16","author":"KA Hoffman","year":"2021","unstructured":"Hoffman KA, Baker R, Fanucchi LC, et al. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. Addict Sci Clin Pract. 2021;16(1):67. https:\/\/doi.org\/10.1186\/s13722-021-00277-z.","journal-title":"Addict Sci Clin Pract"},{"key":"541_CR27","doi-asserted-by":"publisher","unstructured":"Morgan DL, Hoffman KA. A System for Coding the Interaction in Focus Groups and Dyadic Interviews. Qual Rep. Published online March 3, 2018. https:\/\/doi.org\/10.46743\/2160-3715\/2018.2733","DOI":"10.46743\/2160-3715\/2018.2733"},{"key":"541_CR28","volume-title":"Oxford bibliographies in communication","author":"K Hoffman","year":"2017","unstructured":"Hoffman K, Ponce-Terashima J. Focus groups. In: Hoffman K, editor. Oxford bibliographies in communication. Oxford: Oxford University Press; 2017."},{"key":"541_CR29","doi-asserted-by":"publisher","DOI":"10.4135\/9781526416070","volume-title":"The SAGE Handbook of Qualitative Data Collection","author":"D Morgan","year":"2018","unstructured":"Morgan D, Hoffman K. Focus Groups. In: Morgan D, editor. The SAGE Handbook of Qualitative Data Collection. London: SAGE Publications Ltd; 2018. https:\/\/doi.org\/10.4135\/9781526416070."},{"issue":"2","key":"541_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"key":"541_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12888-017-1242-1","volume":"17","author":"M Haugum","year":"2017","unstructured":"Haugum M, Iversen HH, Bjertnaes O, Lindahl AK. Patient experiences questionnaire for interdisciplinary treatment for substance dependence (PEQ-ITSD): reliability and validity following a national survey in Norway. BMC Psychiatry. 2017;17:73. https:\/\/doi.org\/10.1186\/s12888-017-1242-1.","journal-title":"BMC Psychiatry"},{"key":"541_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fpsyt.2016.00211","volume":"7","author":"B Hay","year":"2016","unstructured":"Hay B, Henderson C, Maltby J, Canales JJ. Influence of peer-based needle exchange programs on mental health status in people who inject drugs: a nationwide New Zealand study. Front Psychiatry. 2016;7:211. https:\/\/doi.org\/10.3389\/fpsyt.2016.00211.","journal-title":"Front Psychiatry"},{"key":"541_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13011-015-0040-3","volume":"10","author":"B Myers","year":"2015","unstructured":"Myers B, Govender R, Koch JR, Manderscheid R, Johnson K, Parry CDH. Development and psychometric validation of a novel patient survey to assess perceived quality of substance abuse treatment in South Africa. Subst Abuse Treat Prev Policy. 2015;10:44. https:\/\/doi.org\/10.1186\/s13011-015-0040-3.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"541_CR34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/nhs.12173","volume":"17","author":"A Clements","year":"2015","unstructured":"Clements A, Grose J, Skirton H. Experiences of UK patients with hepatitis C virus infection accessing phlebotomy: a qualitative analysis. Nurs Health Sci. 2015;17(2):214\u201322. https:\/\/doi.org\/10.1111\/nhs.12173.","journal-title":"Nurs Health Sci"},{"issue":"4","key":"541_CR35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/nhs.12231","volume":"17","author":"C Ferguson","year":"2015","unstructured":"Ferguson C, Higgs P, Olsen A. Jugular venipuncture and other innovative approaches to phlebotomy among people who inject drugs. Nurs Health Sci. 2015;17(4):539\u201341. https:\/\/doi.org\/10.1111\/nhs.12231.","journal-title":"Nurs Health Sci"},{"issue":"5","key":"541_CR36","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s10461-020-03141-4","volume":"25","author":"A Seaman","year":"2021","unstructured":"Seaman A, Leichtling G, Stack E, et al. Harm reduction and adaptations among PWUD in rural oregon during COVID-19. AIDS Behav. 2021;25(5):1331\u20139. https:\/\/doi.org\/10.1007\/s10461-020-03141-4.","journal-title":"AIDS Behav"},{"key":"541_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-05311-0","author":"D Collins","year":"2019","unstructured":"Collins D, Alla J, Nicolaidis C, et al. \u201cIf it wasn\u2019t for him, i wouldn\u2019t have talked to them\u201d: qualitative study of addiction peer mentorship in the hospital. J Gen Intern Med. 2019. https:\/\/doi.org\/10.1007\/s11606-019-05311-0.","journal-title":"J Gen Intern Med"},{"key":"541_CR38","doi-asserted-by":"publisher","DOI":"10.4172\/2573-4571.1000122","author":"C Mailloux","year":"2018","unstructured":"Mailloux C, Halesey E. Patient Navigators as Essential Members of the Healthcare Team: A Review of the Literature. Med Imaging Fac Scholarsh. 2018. https:\/\/doi.org\/10.4172\/2573-4571.1000122.","journal-title":"Med Imaging Fac Scholarsh"},{"issue":"1","key":"541_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13722-023-00365-2","volume":"18","author":"JL Taylor","year":"2023","unstructured":"Taylor JL, Wakeman SE, Walley AY, Kehoe LG. Substance use disorder bridge clinics: models, evidence, and future directions. Addict Sci Clin Pract. 2023;18(1):23. https:\/\/doi.org\/10.1186\/s13722-023-00365-2.","journal-title":"Addict Sci Clin Pract"},{"key":"541_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108283","volume":"124","author":"SA Clark","year":"2021","unstructured":"Clark SA, Davis C, Wightman RS, et al. Using telehealth to improve buprenorphine access during and after COVID-19: a rapid response initiative in Rhode Island. J Subst Abuse Treat. 2021;124: 108283. https:\/\/doi.org\/10.1016\/j.jsat.2021.108283.","journal-title":"J Subst Abuse Treat"},{"key":"541_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108444","volume":"131","author":"BM Buchheit","year":"2021","unstructured":"Buchheit BM, Wheelock H, Lee A, Brandt K, Gregg J. Low-barrier buprenorphine during the COVID-19 pandemic: a rapid transition to on-demand telemedicine with wide-ranging effects. J Subst Abuse Treat. 2021;131: 108444. https:\/\/doi.org\/10.1016\/j.jsat.2021.108444.","journal-title":"J Subst Abuse Treat"},{"issue":"7","key":"541_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18223","volume":"4","author":"PJ Joudrey","year":"2021","unstructured":"Joudrey PJ, Adams ZM, Bach P, et al. Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada. JAMA Netw Open. 2021;4(7): e2118223. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.18223.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"541_CR43","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","volume":"46","author":"JJ Lister","year":"2020","unstructured":"Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46(3):273\u201388. https:\/\/doi.org\/10.1080\/00952990.2019.1694536.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"541_CR44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.drugpo.2009.10.010","volume":"21","author":"JF Kelly","year":"2010","unstructured":"Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy. 2010;21(3):202\u20137. https:\/\/doi.org\/10.1016\/j.drugpo.2009.10.010.","journal-title":"Int J Drug Policy"},{"issue":"1\u20132","key":"541_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","volume":"131","author":"LC van Boekel","year":"2013","unstructured":"van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend. 2013;131(1\u20132):23\u201335. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.02.018.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"541_CR46","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10826084.2017.1363238","volume":"53","author":"SE Wakeman","year":"2018","unstructured":"Wakeman SE, Rich JD. Barriers to medications for addiction treatment: how stigma kills. Subst Use Misuse. 2018;53(2):330\u20133. https:\/\/doi.org\/10.1080\/10826084.2017.1363238.","journal-title":"Subst Use Misuse"},{"key":"541_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.drugpo.2017.05.031","volume":"47","author":"O Bonnington","year":"2017","unstructured":"Bonnington O, Harris M. Tensions in relation: how peer support is experienced and received in a hepatitis C treatment intervention. Int J Drug Policy. 2017;47:221\u20139. https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.031.","journal-title":"Int J Drug Policy"},{"issue":"Suppl 5","key":"541_CR48","doi-asserted-by":"publisher","first-page":"v17","DOI":"10.1093\/jac\/dkz452","volume":"74","author":"J Surey","year":"2019","unstructured":"Surey J, Menezes D, Francis M, et al. From peer-based to peer-led: redefining the role of peers across the hepatitis C care pathway: HepCare Europe. J Antimicrob Chemother. 2019;74(Suppl 5):v17\u201323. https:\/\/doi.org\/10.1093\/jac\/dkz452.","journal-title":"J Antimicrob Chemother"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00541-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00541-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00541-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T07:01:37Z","timestamp":1738998097000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00541-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00541-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}